Comparative Pharmacology
Head-to-head clinical analysis: ALTOPREV versus OMTRYG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTOPREV versus OMTRYG.
ALTOPREV vs OMTRYG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to upregulation of LDL receptors and increased clearance of LDL cholesterol.
OMTRYG is a combination of ombitasvir, paritaprevir, and ritonavir. Ombitasvir is an NS5A inhibitor that blocks viral RNA replication and assembly. Paritaprevir is an NS3/4A protease inhibitor that prevents viral polyprotein cleavage. Ritonavir is a CYP3A4 inhibitor used to boost paritaprevir levels.
Lovastatin extended-release: Initial 20, 40, or 60 mg orally once daily at bedtime; titrate every 4 weeks; max 60 mg/day.
2 mg orally twice daily; if taste disturbance occurs, reduce to 1 mg twice daily.
None Documented
None Documented
14 hours (terminal); extended-release formulation allows once-daily dosing
Terminal elimination half-life is 12-14 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life prolongs to 24-36 hours requiring dose adjustment.
Renal (10% as active metabolites, 83% as inactive metabolites in urine); fecal (5%)
Primarily renal excretion unchanged (approximately 70%), with 30% metabolized hepatically and excreted in feces via bile. Renal clearance accounts for ~60% of total clearance.
Category C
Category C
HMG-CoA Reductase Inhibitor (Statin)
HMG-CoA Reductase Inhibitor (Statin)